• About
  • Partnerships
  • Challenges
  • Awards
  • Grant Opportunities
  • News

Toll-Like Receptor 8 Agonists as Novel Neonatal Vaccine Adjuvants

Ofer Levy at Children's Hospital Boston in the U.S. will determine whether synthetic molecules called imidazoquinolines activate newborns' white blood cells, and could be used as candidate vaccine adjuvants to dramatically enhance immunization at birth. In this project's Phase I research, Levy demonstrated that Toll-like Receptor-7 and -8 agonists are superior to agonists of other Toll-like receptors and to alum, an already approved vaccine adjuvant, in activating newborn immune responses in studies in vitro. In Phase II, Levy will conduct in vivo studies to test the ability of these molecules to boost vaccine responses, evaluating both the safety and efficacy of this approach.

More information about Create New Ways of Protecting Against Infectious Diseases (Round 2)

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

The Bill & Melinda Gates Foundation is part of the Grand Challenges partnership network. Visit www.grandchallenges.org to view the map of awarded grants across this network and grant opportunities from partners.